Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 15367657 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Luo H, et al. (2004) A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment. Mol Cell Biol 24, 8356-65 15367657
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S461-p - XRCC1 (human) ▲
Orthologous residues
XRCC1 (human): S461‑p, XRCC1 var1 (human): S461‑p, XRCC1 (mouse): S460‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  EM9 cells

S475-p - XRCC1 (human) ▲
Orthologous residues
XRCC1 (human): S475‑p, XRCC1 var1 (human): S475‑p, XRCC1 (mouse): S474‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  EM9 cells
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)

S485-p - XRCC1 (human) ▲
Orthologous residues
XRCC1 (human): S485‑p, XRCC1 var1 (human): S485‑p, XRCC1 (mouse): S484‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  EM9 cells
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE CK2-A2 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme

T488-p - XRCC1 (human) ▲
Orthologous residues
XRCC1 (human): T488‑p, XRCC1 var1 (human): T488‑p, XRCC1 (mouse): T487‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  EM9 cells
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE CK2-A2 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme

S518-p - XRCC1 (human) ▲
Orthologous residues
XRCC1 (human): S518‑p, XRCC1 var1 (human): S518‑p, XRCC1 (mouse): S517‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  EM9 cells
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE CK2-A2 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MMS no change compared to control
TBB decrease
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Pnk1 (human) Induces co-immunoprecipitation
APTX (human) FHA Induces co-immunoprecipitation, pull-down assay

T519-p - XRCC1 (human) ▲
Orthologous residues
XRCC1 (human): T519‑p, XRCC1 var1 (human): T519‑p, XRCC1 (mouse): T518‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  EM9 cells
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE CK2-A2 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MMS no change compared to control
TBB decrease
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Pnk1 (human) Induces co-immunoprecipitation
APTX (human) FHA Induces co-immunoprecipitation, pull-down assay

T523-p - XRCC1 (human) ▲
Orthologous residues
XRCC1 (human): T523‑p, XRCC1 var1 (human): T523‑p, XRCC1 (mouse): T522‑p
Characterization
 Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  293T (epithelial), HeLa (cervical)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  EM9 cells
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A2 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
KINASE CK2-A1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MMS no change compared to control
TBB decrease
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Pnk1 (human) Induces co-immunoprecipitation
APTX (human) FHA Induces co-immunoprecipitation, pull-down assay


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.